Lakefront, in collaboration with Gilead, received Orphan Drug Designation from the FDA for gamgertamig, with trials active globally.

The entities involved

• company →

  legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective

  • Silvercorp Metals Inc. is investigating potential claims on behalf of purchasers.Sun 17:42
  • The board of directors approved a name change proposal for the company on October 25, 2026.Sun 12:37
• Gilead Sciences →

  American company

  • Amgen and Gilead Sciences are two companies that compete within the biotech industry.Sun 11:22
  • Gilead Sciences is commercializing medicines in Europe, with Anu Osinusi as VP of Clinical Development and Cynthia Levy supporting IDEAL results for Livdelzi.Fri 16:08
• FDA →
  • The illegal U.S. vape market is estimated to be worth $9 billion, fueled by unauthorized imports from China, while products must meet FDA authorization standards.Sun 20:36
  • VDPHL01 and Veradermics, Incorporated are seeking FDA approval for their lead therapies targeting hair loss.Sun 20:31

Related events

• Clinical trial sites are currently enrolling patients in the United States, United Kingdom, and Australia.Jun 11
• A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Jun 7
• FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.Jun 22
• EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.Jun 8
• Generic medicine services are seeking approval for launch from the FDA.Sep 28